Dianthus Therapeutics: Katkhuda's Buy Rating Backed by Promising DNTH103 Clinical Prospects and Strategic Positioning

TipRanks31minutes ago

Milestone Pharmaceuticals Analyst Ratings

Benzinga01:42

HC Wainwright & Co. Reiterates Buy on Milestone Pharmaceuticals, Maintains $25 Price Target

Benzinga01:42

Buy Rating for Ovid Therapeutics Backed by Strong Clinical Data and Strategic Management

TipRanks00:59

Skye Bioscience Analyst Ratings

BenzingaJul 1 23:27

Cantor Fitzgerald Reiterates Overweight on Skye Bioscience, Maintains $14 Price Target

BenzingaJul 1 23:26

Cantor Fitzgerald Reiterates Overweight on Novo Nordisk, Maintains $160 Price Target

BenzingaJul 1 23:18

Novo Nordisk Analyst Ratings

BenzingaJul 1 23:17

Cantor Fitzgerald Reiterates Overweight on 89bio, Maintains $29 Price Target

BenzingaJul 1 23:07

89bio Analyst Ratings

BenzingaJul 1 23:05

Sagimet Biosciences Analyst Ratings

BenzingaJul 1 22:14

Sarepta Therapeutics Analyst Ratings

BenzingaJul 1 21:55

Piper Sandler Maintains Overweight on Sarepta Therapeutics, Maintains $205 Price Target

BenzingaJul 1 21:54

Praxis Precision Medicine Analyst Ratings

BenzingaJul 1 21:52

Alnylam Pharmaceuticals Analyst Ratings

BenzingaJul 1 21:49

Edgewise Therapeutics Analyst Ratings

BenzingaJul 1 21:48

Piper Sandler Maintains Overweight on Edgewise Therapeutics, Maintains $48 Price Target

BenzingaJul 1 21:48

Corcept Therapeutics Analyst Ratings

BenzingaJul 1 21:44

Stifel Nicolaus Sticks to Their Buy Rating for Arcellx Inc (ACLX)

TipRanksJul 1 21:34

Avid Bioservices (CDMO) Receives a Buy From Craig-Hallum

TipRanksJul 1 21:32